Home Science & Medicine Targeted Therapy

Targeted Therapy

Feature articles about advances and current developments in targeted therapy that have significant impact or impact potential on thoracic oncology.

Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R....

By Erik J. MacLaren, PhD Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use...

Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD,...

By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line...

Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...

By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...

The Lung Master Protocol (Lung-MAP)

By Vassiliki A. Papadimitrakopoulou, MD Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform...

Q & A with Yi-Long Wu, MD

What is the current standard of care in the adjuvant setting post-resection of high-risk NSCLC in your practice or nationally? Posted: October 2017 Current Chinese Lung...

Clinical Labeling in Medicinal Products: An Interview With Dr. David Planchard About the Effects...

Posted: June 2017 By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization...

ADJUVANT Trial of Gefitinib Versus Chemotherapy in Resected EGFR-Mutations Non-Small Cell Lung Cancer

By Heather Wakelee, MD Posted: October 2017 For most of the world, four cycles of cisplatin-based adjuvant chemotherapy is the standard of care for patients with...

Uncommon Oncogenic Drivers in NSCLC

By Karen L. Reckamp, MD, MS Posted: March 1, 2019  Identification of genetic alterations in NSCLC has transformed diagnosis and treatment for patients with advanced disease....

Meeting News